What is the difference between Argireline and Cartalax?

Argireline: Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects Cartalax: Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Is Argireline FDA approved?

Argireline is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Cartalax FDA approved?

Cartalax is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Argireline administered in research settings?

In research settings, Argireline is typically administered via the topical route. PeptideBase does not provide dosing or administration instructions.

How is Cartalax administered in research settings?

In research settings, Cartalax is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Argireline vs Cartalax

Peptide Comparison

Argireline vs Cartalax

Name: Argireline vs Cartalax — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Skin & Cosmetic peptides.

Argireline

Acetyl Hexapeptide-3

Skin & JointNot EvaluatedResearch Only

Half-life: N/A (topical)

18 providers listed

Full Argireline profile →

Cartalax

Ala-Glu-Asp-Arg

Skin & JointNot EvaluatedResearch Only

Half-life: Unknown

6 providers listed

Full Cartalax profile →

Bottom line

Argireline carries stronger published evidence (RCT, 3 key studies) than Cartalax (In vitro, 1); both are research compounds.

Quick Verdict

Argireline

Evidence

Clinical

Cartalax

Evidence

Preclinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Argireline
Oral administration option	Cartalax
More provider options (18 vs 6)	Argireline

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Argireline

Cartalax

Mechanism Family

Skin & Cosmetic

Half-life

N/A (topical)

Unknown

FDA Status

not evaluated

Admin Routes

topical

subcutaneous, oral

Availability

Research Only

Providers

18 listed

6 listed

Avail. Notes

Cosmetic peptide (acetyl hexapeptide-3). Sold as cosmetic ingredient by Lipotec/Sederma. Not regulated as a drug by FDA. No NDA or IND. Cosmetic anti-wrinkle ingredient only.

Russian joint/cartilage peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Research Evidence

Argireline

ClinicalRCT · 3 key studies · most recent 2026

Cartalax

PreclinicalIn vitro · 1 key study · most recent 2023

Research Citations

Argireline

RCT2013 · American Journal of Clinical Dermatology

The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-…

Cohort2026 · Biomater Adv

DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging.

RCT2017 · Journal of Cosmetic Dermatology

The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3: a prospective, ra…

Cartalax

In vitro2023 · Advances in Gerontology

KE peptide regulates SIRT1, PARP1, PARP2 gene expression and protein synthesis in human mesenchymal stem cell…

About Argireline

Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects

Research Areas

SNARE complex (SNAP-25) competitive inhibition reducing expression line depthwrinkle reduction documented in controlled human trialstopical cosmetic application — not a systemic peptidesoftening of dynamic lines over 4–8 weeks at 5–10% concentration

About Cartalax

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Research Areas

cartilage regenerationjoint repairchondrocyte function support

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Argireline

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Cartalax

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

Argireline

Not enough vendor pricing yet.

Cartalax

$2.75/mg

$2.00 – $2.75 range

8 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Argireline

18 listed

Browse directory →

Providers offering

Cartalax

6 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Argireline vs Cartalax — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/argireline/cartalax

https://peptidebase.io/peptides/compare/argireline/cartalax Methodology License Download JSON Download CSV